Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Pedrola MT"" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".
Autorzy:
Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Wladysiuk M; Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland.; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
McTaggart S; Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK.
Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Allocati E; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Jakovljevic M; Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia.; Institute of Comparative Economic Studies, Hosei University Tokyo, Japan.; Department of Global Health Economics and Policy, University of Kragujevac, Serbia.
Kalemeera F; Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia.
Hoxha I; Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania.
Nachtnebel A; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Sauermann R; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Hinteregger M; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Marković-Peković V; Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Tubic B; Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina.
Petrova G; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Tachkov K; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Slabý J; State Institute for Drug Control, Prague, Czech Republic.
Nejezchlebova R; State Institute for Drug Control, Prague, Czech Republic.
Krulichová IS; Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic.
Laius O; State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia.
Selke G; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Langner I; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Harsanyi A; Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary.
Inotai A; Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary.
Jakupi A; Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo.
Henkuzens S; Independent Consultant, Riga, Latvia.
Garuolienė K; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Gulbinovič J; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Bonanno PV; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Department of Health Services Management, University of Malta, Valletta, Malta.
Rutkowski J; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
Ingeberg S; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Melien Ø; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania.
Fürst J; Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia.
MacBride-Stewart S; Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK.
Holmes C; NHS Lothian, Edinburgh, UK.
Pontes C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zara C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Pedrola MT; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Hoffmann M; NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden.
Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece.
Pisana A; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Banzi R; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Campbell S; Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK.
Wettermark B; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2023 Apr 07; Vol. 2023, pp. 9757348. Date of Electronic Publication: 2023 Apr 07 (Print Publication: 2023).
Typ publikacji:
Published Erratum
Tytuł:
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Autorzy:
Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Wladysiuk M; Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland.; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
McTaggart S; Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK.
Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Allocati E; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Jakovljevic M; Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia.; Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Tokyo, Japan.
Kalemeera F; Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia.
Hoxha I; Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania.
Nachtnebel A; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Sauermann R; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Hinteregger M; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Marković-Peković V; Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Tubic B; Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina.
Petrova G; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Tachkov K; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Slabý J; State Institute for Drug Control, Prague, Czech Republic.
Nejezchlebova R; State Institute for Drug Control, Prague, Czech Republic.
Krulichová IS; Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic.
Laius O; State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia.
Selke G; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Langner I; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Harsanyi A; Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary.
Inotai A; Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary.
Jakupi A; Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo.
Henkuzens S; Independent Consultant, Riga, Latvia.
Garuolienė K; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Gulbinovič J; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Bonanno PV; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Department of Health Services Management, University of Malta, Valletta, Malta.
Rutkowski J; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
Ingeberg S; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Melien Ø; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania.
Fürst J; Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia.
MacBride-Stewart S; Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK.
Holmes C; NHS Lothian, Edinburgh, UK.
Pontes C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zara C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Pedrola MT; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Hoffmann M; NEPI-Nätverk för läkemedelsepidemiologi, Stockholm, Sweden.
Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece.
Pisana A; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Banzi R; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Campbell S; Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK.
Wettermark B; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2021 Oct 11; Vol. 2021, pp. 9996193. Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).
Typ publikacji:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals/*therapeutic use
Cost-Benefit Analysis/*trends
Diabetes Mellitus/*drug therapy
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Insulin, Long-Acting/*therapeutic use
Patient Education as Topic/*methods
Biosimilar Pharmaceuticals/economics ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/economics ; Europe ; Humans ; Hypoglycemic Agents/economics ; Insulin Glargine/economics ; Insulin, Long-Acting/economics
Czasopismo naukowe
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies